Key result
A single intravenous dose of furosemide increased urinary aquaporin-2 excretion, urine volume, and free water clearance in CHF patients.
Why the study?
Does a single intravenous dose of furosemide increase urinary aquaporin-2 excretion in patients with chronic heart failure?
RCT (n=12)
single-blind
randomized crossover
Does a single intravenous dose of furosemide increase urinary aquaporin-2 excretion in patients with chronic heart failure?
In patients with chronic heart failure, furosemide induces a compensatory increase in vasopressin and aquaporin-2-mediated water reabsorption, though its net diuretic and natriuretic effects prevail.
Answers are grounded in this paper and cite their sources.
Furosemide's net diuresis prevails over compensatory AQP2 rise in CHF; extends evidence for vasopressin counter-regulation to loop diuretics.
OBJECTIVE: Patients with chronic heart failure (CHF) have decreased ability to excrete water and increased urinary excretion of aquaporin-2 (U-AQP2). The natriuretic and diuretic effects of furosemide are antagonized by an increased reabsorption of sodium and water in the collecting ducts. It is unknown whether aquaporin-2 (AQP2) renal water channels are involved in this compensatory reabsorption. We tested the hypothesis that U-AQP2 increases after a single intravenous dose of furosemide in CHF patients. MATERIAL AND METHODS: In a randomized, single-blind, placebo-controlled, crossover study, we measured the effect of furosemide (80 mg) on U-AQP2, urine volume, free water clearance (C(H2O)) and fractional excretion of sodium (FE(Na)) in 12 CHF patients. Plasma concentrations of vasopressin (AVP), renin (PRC), angiotensin II (Ang II), aldosterone (Aldo), atrial (ANP) and brain natriuretic peptides (BNP) were measured during the study. U-AQP2 and hormones were determined by radioimmunoassays. RESULTS: Furosemide increased U-AQP2 (140 %), urine volume (280 %), C(H2O) (95 %) and FE(Na) by a factor of 15 (p<0.008 for all), and also AVP (51 %), PRC, Ang II (86 %) and Aldo (59 %) (p<0.021 for all). ANP and BNP did not change. CONCLUSIONS: In CHF, furosemide increased the vasopressin level, which stimulated water reabsorption via the APQ2 water channels. This is most likely a compensatory phenomenon in addition to the increase in the renin-angiotensin system to prevent excess loss of sodium and water. However, both these effects were overridden by the effect of furosemide, as shown by increased free water clearance and sodium excretion.
No takes yet. Share an insight, caveat, or question.
Starklint et al. (2006) conducted an RCT in chronic heart failure (n=12). furosemide vs. placebo was evaluated on urinary excretion of aquaporin-2 (U-AQP2), urine volume, free water clearance, and fractional excretion of sodium (p=<0.008). A single intravenous dose of furosemide increased urinary aquaporin-2 excretion, urine volume, and free water clearance in CHF patients.
Synapse has enriched 10 related papers. Consider them for comparative context: